Interview: Has UK Medtech Happened Upon A Perfect Opportunity For Disruptive Regulatory Change?
The UKCA mark and new device legislation could open doors onto a bigger global role for the MHRA
Executive Summary
ABHI’s Phil Brown looks beyond the immediate challenges for UK medtechs on being outside the EU, and to an innovation-friendly, patient-responsive system of future regulation.
You may also be interested in...
‘MDD+’ For The UK, As Future Devices Regulation Will Be A ‘Living Document’
With the UK implementing sovereign device legislation after leaving the EU, there are opportunities for incorporating updated EU and US FDA provisions as regulation evolves.
Lack Of Joined Up Data Must Be Addressed By Registries In New UK Device Legislation
The Cumberlege Review of patient safety delivered a damning verdict on the UK’s health system. Its recommendations must be acted on, says a consensus of stakeholders.
UKCA Mark Will Be The Post-EU Route To The British Medtech Market In January 2021
New MHRA guidance says the EU CE marking will continue to be used for devices and diagnostics in Great Britain until June 2023, and thereafter a standalone regulatory system will come into place.